Silicom Ltd. (SILC) At $35.47 Forms Top; Palo Alto Investors Has Cut Its United Therapeutics Del (UTHR) Stake

April 6, 2018 - By Annabelle Johnson

United Therapeutics Corporation (NASDAQ:UTHR) Logo

Silicom Ltd. (SILC) formed multiple top with $36.89 target or 4.00% above today’s $35.47 share price. Silicom Ltd. (SILC) has $267.78 million valuation. The stock increased 0.54% or $0.19 during the last trading session, reaching $35.47. About 131,365 shares traded. Silicom Ltd. (NASDAQ:SILC) has declined 24.78% since April 6, 2017 and is downtrending. It has underperformed by 36.33% the S&P500.

Palo Alto Investors Llc decreased United Therapeutics Corp Del (UTHR) stake by 8.87% reported in 2017Q4 SEC filing. Palo Alto Investors Llc sold 156,400 shares as United Therapeutics Corp Del (UTHR)’s stock declined 21.89%. The Palo Alto Investors Llc holds 1.61M shares with $237.65M value, down from 1.76M last quarter. United Therapeutics Corp Del now has $4.89 billion valuation. The stock decreased 2.85% or $3.31 during the last trading session, reaching $113.03. About 404,395 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has declined 23.69% since April 6, 2017 and is downtrending. It has underperformed by 35.24% the S&P500.

Since October 5, 2017, it had 0 insider buys, and 9 sales for $15.01 million activity. $2.40 million worth of United Therapeutics Corporation (NASDAQ:UTHR) shares were sold by ROTHBLATT MARTINE A. CAUSEY CHRISTOPHER also sold $70,760 worth of United Therapeutics Corporation (NASDAQ:UTHR) shares.

Palo Alto Investors Llc increased Alexion Pharmaceuticals Inc (NASDAQ:ALXN) stake by 37,300 shares to 1.12M valued at $133.66 million in 2017Q4. It also upped Immunomedics Inc (NASDAQ:IMMU) stake by 1.76M shares and now owns 4.77 million shares. Bioverativ Inc was raised too.

Analysts await United Therapeutics Corporation (NASDAQ:UTHR) to report earnings on April, 25. They expect $3.64 EPS, down 6.43% or $0.25 from last year’s $3.89 per share. UTHR’s profit will be $157.38M for 7.76 P/E if the $3.64 EPS becomes a reality. After $2.06 actual EPS reported by United Therapeutics Corporation for the previous quarter, Wall Street now forecasts 76.70% EPS growth.

United Therapeutics Corporation (NASDAQ:UTHR) Institutional Positions Chart